Dr. Hilde Hermansen Steineger, Ph.d.
Independent Director
Pharmaceutical technology
Redpoint Research
New Zealand
Biography
Dr. Hilde Hermansen Steineger, Ph.D. has been Independent Director at NORDIC NANOVECTOR ASA since November 12, 2014. She is Chair of the Audit Committee and Member of Remuneration Committee. She is Head of Innovation Management at Pronova BioPharma ASA / BASF, a global leader in the research, development and manufacture of marine-originated omega-3 derived pharmaceutical products. Previously, Hilde Steineger was VP Investor Relations and Communications at Pronova BioPharma and prior to that she was Senior Associate with Neomed Management, an international investment firm focusing on the healthcare and life science industry. From 2004 to 2006, she worked as an independent advisor focusing on start-ups within the Life Science/Health Care sector, and before that, she was an equity analyst at Kreditkassen (now part of Nordea Markets) based in Oslo and Copenhagen (2001-2004). Hilde Steineger began her professional career at Nycomed Pharma, where she worked in the area of clinical research and international marketing from 1999 to 2001. Current board positions include: Strongbridge BioPharma and PCI Biotech. She holds a Bachelor of Science and a Ph.D. in Medical Biochemistry from the University of Oslo.
Research Interest
Nanomedicine Design of Nanodrugs Personalized Nanomedicine Nanomaterials for drug delivery
